Insider Transactions in Q4 2024 at Athira Pharma, Inc. (ATHA)
Insider Transaction List (Q4 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 31
2024
|
Martin Javier San CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
46,667
+50.0%
|
-
|
|
Dec 31
2024
|
Mark Worthington General Counsel and CCO |
BUY
Exercise of conversion of derivative security
|
Direct |
36,667
+28.44%
|
-
|
|
Dec 31
2024
|
Robert Renninger VP of Finance |
BUY
Exercise of conversion of derivative security
|
Direct |
12,359
+11.77%
|
-
|
|
Dec 31
2024
|
Kevin Church CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
36,667
+20.84%
|
-
|
|
Dec 31
2024
|
Mark James Litton President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
108,333
+28.81%
|
-
|
|
Nov 18
2024
|
Mark Worthington General Counsel and CCO |
BUY
Grant, award, or other acquisition
|
Direct |
3,651
+6.16%
|
$0
$0.55 P/Share
|
|
Nov 18
2024
|
Robert Renninger VP of Finance |
BUY
Grant, award, or other acquisition
|
Direct |
3,651
+4.35%
|
$0
$0.55 P/Share
|
|
Nov 18
2024
|
Kevin Church CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
9,920
+8.82%
|
$0
$0.55 P/Share
|